177Lu-FAP-VG11
/ Vitsgen Therapeutics, Shandong Cancer Institute
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 09, 2026
Clinical Evaluation of 177Lu-FAP-VG11 Injection in Patients With Fibroblast Activation Protein -Positive Advanced Solid Tumours
(clinicaltrials.gov)
- P1 | N=7 | Recruiting | Sponsor: Shandong Cancer Hospital and Institute
New P1 trial • Oncology • Solid Tumor • FAP
1 to 1
Of
1
Go to page
1